Results 21 to 30 of about 6,174,751 (218)

CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia

open access: yesBiomolecules & Biomedicine, 2023
Quantification of measurable residual disease (MRD) correlates with the risk of leukemia recurrence in adults with B-cell acute lymphoblastic leukemia (ALL).
Lei-Ming Cao   +16 more
doaj   +1 more source

Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation [PDF]

open access: yes, 2012
Background: Reconstitution of cytomegalovirus-specific CD3+CD8+ T cells (CMV-CTLs) after allogeneic hematopoietic stem cell transplantation (HSCT) is necessary to bring cytomegalovirus (CMV) reactivation under control. However, the parameters determining
Matthias Eder (21135)   +74 more
core   +2 more sources

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma [PDF]

open access: yes, 2004
We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10 ...
Mahendra, P   +37 more
core   +1 more source

Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide [PDF]

open access: yes, 2021
Severe infections and their attributable mortality are major complications in recipients of allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult patients who received haploSCT with PTCy.
Martino Bofarull, Rodrigo   +36 more
core   +1 more source

Hematopoietic stem cell transplantation

open access: yesStem Cells and Cloning: Advances and Applications, 2010
More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes.
Hatzimichael,Eleftheria, Tuthill,Mark
openaire   +5 more sources

Hematopoietic stem cell transplantation in thalassemia [PDF]

open access: yesBone Marrow Transplantation, 2008
SCT still remains the only cure currently available for patients with thalassemia. Results of transplants in this disease have steadily improved over the last two decades due to improvements in preventive strategies, effective control of transplant-related complications and development of new preparative regimens.
J, Gaziev, P, Sodani, G, Lucarelli
openaire   +2 more sources

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia

open access: yesJournal of Hematology & Oncology, 2017
Background The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t ...
Ya-Zhen Qin   +14 more
doaj   +1 more source

Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway

open access: yesFrontiers in Pharmacology, 2021
Hepatocellular carcinoma (HCC) is the most prevalent subtype of liver cancer with a mortality rate of approximately 3–6/100,000 and is the third leading cause of cancer-related death worldwide.
Haina Wang   +13 more
doaj   +1 more source

Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1 [PDF]

open access: yes, 2007
Background: AML1/RUNX1 is the most frequently mutated gene in leukaemia and is central to the normal biology of hematopoietic stem and progenitor cells. However, the role of different AML1 isoforms within these primitive compartments is unclear.
Hong, DL   +18 more
core   +1 more source

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis

open access: yesExperimental Hematology & Oncology, 2017
Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have
Mauricio Sarmiento Maldonado   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy